Intercept Pharmaceuticals traded at $19.00 this Tuesday November 7th, increasing $0.04 or 0.21 percent since the previous trading session. Looking back, over the last four weeks, Intercept Pharmaceuticals gained 1.99 percent. Over the last 12 months, its price rose by 23.06 percent. Looking ahead, we forecast Intercept Pharmaceuticals to be priced at 18.43 by the end of this quarter and at 16.81 in one year, according to Trading Economics global macro models projections and analysts expectations.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. The Company’s product candidates include Ocaliva (obeticholic or OCA) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. In addition to commercializing OCA for PBC, it is also developing OCA for additional indications, including NASH. The Company is also developing product candidates in various stages of clinical and preclinical development.